Biopharma | April 16, 2026
Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
To boost compostable packaging, resin innovation, and supply chain speed
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
Minister highlights scope for domestic manufacturing during his meeting with Dr Niti Pall, President-elect, International Diabetes Federation
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Subscribe To Our Newsletter & Stay Updated
